Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses

K Berankova, M Szkutova, M Balikova

. 2007 ; 170 (2-3) : 94-99.

Jazyk angličtina Země Irsko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10011886

Grantová podpora
NR8332 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online

NLK ProQuest Central od 1997-02-07 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 1997-02-07 do Před 2 měsíci
Health & Medicine (ProQuest) od 1997-02-07 do Před 2 měsíci
ScienceDirect (archiv) od 1993-01-01 do 2009-12-31

2,5-Dimethoxy-4-bromoamphetamine (DOB) is one of the potent hallucinogenic phenylalkylamines, whose ingestion has already caused several deaths reported all over the world. However, there is insufficient information on DOB properties based on controlled pharmacokinetic studies available. The aim of this study was to clarify the distribution profile of DOB and its phenolic metabolite 2-methoxy-5-hydroxy-4-bromoamphetamine (2M5H4BA) in blood and biological tissues of experimental rats. The rats were administered a 20 mg/kg dose of DOB.HCl by oral ingestion or subcutaneous injection. Plasma and brain, liver and lung tissues were collected at 0.5, 1, 2, 4, 8, 16, and 32 h after dosing (three animals per time point). The samples were prepared by a liquid-liquid extraction procedure and the extracts were assayed by GC-MS. After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL. A rapid phase of DOB absorption, 2M5H4BA formation and their tissue distribution during the first two hours after application were followed by a slow decrease rate of the elimination process until 32 h. After subcutaneous application, high plasma levels of the unchanged parent drug and relatively reduced formation of its metabolite 2M5H4BA were observed. DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL. The concentration profiles of both compounds in plasma after per oral and subcutaneous administration revealed the existence of significant first pass effect after per oral administration that significantly affected DOB bioavailability. DOB tissue concentrations exceeded plasma and the highest values were found in the lungs, where drug accumulation occurred with prolonged retention till 32 h after subcutaneous dose. Although the plasma/tissue transfer was more effective for the lipophilic parent drug than for its hydroxylated metabolite 2M5H4BA, the metabolite tissue levels were significant. The hallucinogenic potential of 2M5H4BA appearing in brain remains unclear as nothing is known about its pharmacological activity at present.

000      
04054naa 2200457 a 4500
001      
bmc10011886
003      
CZ-PrNML
005      
20131014145807.0
008      
100517s2007 ie e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Beránková, Kateřina. $7 _AN040693
245    10
$a Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses / $c K Berankova, M Szkutova, M Balikova
314    __
$a Institute of Forensic Medicine and Toxicology, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic.
520    9_
$a 2,5-Dimethoxy-4-bromoamphetamine (DOB) is one of the potent hallucinogenic phenylalkylamines, whose ingestion has already caused several deaths reported all over the world. However, there is insufficient information on DOB properties based on controlled pharmacokinetic studies available. The aim of this study was to clarify the distribution profile of DOB and its phenolic metabolite 2-methoxy-5-hydroxy-4-bromoamphetamine (2M5H4BA) in blood and biological tissues of experimental rats. The rats were administered a 20 mg/kg dose of DOB.HCl by oral ingestion or subcutaneous injection. Plasma and brain, liver and lung tissues were collected at 0.5, 1, 2, 4, 8, 16, and 32 h after dosing (three animals per time point). The samples were prepared by a liquid-liquid extraction procedure and the extracts were assayed by GC-MS. After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL. A rapid phase of DOB absorption, 2M5H4BA formation and their tissue distribution during the first two hours after application were followed by a slow decrease rate of the elimination process until 32 h. After subcutaneous application, high plasma levels of the unchanged parent drug and relatively reduced formation of its metabolite 2M5H4BA were observed. DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL. The concentration profiles of both compounds in plasma after per oral and subcutaneous administration revealed the existence of significant first pass effect after per oral administration that significantly affected DOB bioavailability. DOB tissue concentrations exceeded plasma and the highest values were found in the lungs, where drug accumulation occurred with prolonged retention till 32 h after subcutaneous dose. Although the plasma/tissue transfer was more effective for the lipophilic parent drug than for its hydroxylated metabolite 2M5H4BA, the metabolite tissue levels were significant. The hallucinogenic potential of 2M5H4BA appearing in brain remains unclear as nothing is known about its pharmacological activity at present.
650    _2
$a 2,5-dimethoxy-4-methylamfetamin $x aplikace a dávkování $7 D004290
650    _2
$a 2,5-dimethoxy-4-methylamfetamin $x analogy a deriváty $x farmakokinetika $x krev $7 D004290
650    _2
$a aplikace orální $7 D000284
650    _2
$a zvířata $7 D000818
650    _2
$a mozek - chemie $7 D001923
650    _2
$a soudní toxikologie $7 D053593
650    _2
$a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
650    _2
$a halucinogeny $x aplikace a dávkování $x farmakokinetika $x krev $7 D006213
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a játra $x chemie $7 D008099
650    _2
$a plíce $x chemie $7 D008168
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a tkáňová distribuce $7 D014018
650    _2
$a financování organizované $7 D005381
700    1_
$a Rohanová, Miroslava $7 xx0146000
700    1_
$a Balíková, Marie, $d 1945- $7 jn99240000049
773    0_
$t Forensic Science International $w MED00001844 $g Roč. 170, č. 2-3 (2007), s. 94-99 $x 0379-0738
910    __
$a ABA008 $b x $y 8 $z 0
990    __
$a 20100525162035 $b ABA008
991    __
$a 20131014150334 $b ABA008
999    __
$a ok $b bmc $g 725744 $s 588896
BAS    __
$a 3
BMC    __
$a 2007 $b 170 $c 2-3 $d 94-99 $m Forensic science international $n Forensic Sci Int $x MED00001844 $i 0379-0738
GRA    __
$a NR8332 $p MZ0
LZP    __
$a 2010-B2/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...